These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 12692609)
1. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Raiola AM; Van Lint MT; Valbonesi M; Lamparelli T; Gualandi F; Occhini D; Bregante S; di Grazia C; Dominietto A; Soracco M; Romagnani C; Vassallo F; Casini M; Bruno B; Frassoni F; Bacigalupo A Bone Marrow Transplant; 2003 Apr; 31(8):687-93. PubMed ID: 12692609 [TBL] [Abstract][Full Text] [Related]
2. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886 [TBL] [Abstract][Full Text] [Related]
3. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation. Bacigalupo A; Soracco M; Vassallo F; Abate M; Van Lint MT; Gualandi F; Lamparelli T; Occhini D; Mordini N; Bregante S; Figari O; Benvenuto F; Sessarego M; Fugazza G; Carlier P; Valbonesi M Bone Marrow Transplant; 1997 May; 19(9):927-32. PubMed ID: 9156268 [TBL] [Abstract][Full Text] [Related]
4. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft. Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494 [TBL] [Abstract][Full Text] [Related]
5. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes. Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; Moreno-Lafont M; García-Latorre E; Ramírez-Sanjuan E; Montiel-Cervantes L; Tripp-Villanueva F; García-León LD; Ayala-Sánchez M; Rosas-Cabral A; Aviña-Zubieta JA; Galindo-Rodríguez G; Vadillo-Buenfil M; Salazar-Exaire D Ann Hematol; 2004 May; 83(5):295-301. PubMed ID: 15060749 [TBL] [Abstract][Full Text] [Related]
6. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells. Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267 [TBL] [Abstract][Full Text] [Related]
7. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease? Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E; Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175 [TBL] [Abstract][Full Text] [Related]
8. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659 [TBL] [Abstract][Full Text] [Related]
9. [Complete cytogenetic response obtained with unrelated donor lymphocyte infusion for relapse of chronic myeloid leukemia in blastic crisis after allogeneic bone marrow transplantation]. Fujimaki K; Maruta A; Yoshida M; Yamazaki E; Matsuzaki M; Fujisawa S; Kanamori H; Ishigatsubo Y Rinsho Ketsueki; 2001 Mar; 42(3):204-8. PubMed ID: 11345783 [TBL] [Abstract][Full Text] [Related]
10. [Treatment of leukemia relapsed after allogenic bone marrow transplantation with donor lymphocyte infusion: report of 11 cases]. Sanz Rodríguez C; Steegmann JL; Granda A; de la Cámara R; Figuera A; Arranz R; Gómez-García de Soria V; Alegre A; Fernández-Rañada JM Sangre (Barc); 1999 Dec; 44(6):456-63. PubMed ID: 10822760 [TBL] [Abstract][Full Text] [Related]
11. Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation. Ferrá C; Rodríguez-Luaces M; Gallardo D; Encuentra M; Martín-Henao GA; Peris J; Ancín I; Sarrá J; Berlanga JJ; García J; Grañena A Bone Marrow Transplant; 2001 Nov; 28(10):963-8. PubMed ID: 11753552 [TBL] [Abstract][Full Text] [Related]
12. The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse. Carlens S; Remberger M; Aschan J; Ringdén O Biol Blood Marrow Transplant; 2001; 7(1):31-8. PubMed ID: 11215696 [TBL] [Abstract][Full Text] [Related]
13. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408 [TBL] [Abstract][Full Text] [Related]
14. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase. Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121 [TBL] [Abstract][Full Text] [Related]
15. Monitoring of lineage-specific chimaerism allows early prediction of response following donor lymphocyte infusions for relapsed chronic myeloid leukaemia. Gardiner N; Lawler M; O'Riordan JM; Duggan C; De Arce M; McCann SR Bone Marrow Transplant; 1998 Apr; 21(7):711-9. PubMed ID: 9578312 [TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. van Rhee F; Savage D; Blackwell J; Orchard K; Dazzi F; Lin F; Chase A; Bungey J; Cross NC; Apperley J; Szydlo R; Goldman JM Bone Marrow Transplant; 1998 May; 21(10):1055-61. PubMed ID: 9632281 [TBL] [Abstract][Full Text] [Related]
17. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease. de Lima M; Bonamino M; Vasconcelos Z; Colares M; Diamond H; Zalcberg I; Tavares R; Lerner D; Byington R; Bouzas L; da Matta J; Andrade C; Carvalho L; Pires V; Barone B; Maciel C; Tabak D Bone Marrow Transplant; 2001 Jan; 27(1):73-8. PubMed ID: 11244440 [TBL] [Abstract][Full Text] [Related]
18. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse. Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011 [TBL] [Abstract][Full Text] [Related]